Next-Gen Genetic Medicine
MeiraGTx (meiragtx.com) scores 79 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 68th percentile of 16303 Healthcare brands.
MeiraGTx is a clinical-stage genetic medicine company with a global footprint that develops gene therapies intended to provide potentially curative treatments for patients with serious rare and prevalent diseases. The company works across research, clinical development, and manufacturing of genetic therapies, aiming to serve patients, healthcare providers, researchers, and biopharmaceutical partners. It positions itself as a pioneer in next-generation gene therapy innovation within the healthcare and biotechnology sector.
| Brand Name | MeiraGTx |
|---|---|
| Domain | meiragtx.com |
| Industry | Healthcare |
| Main Competitors | Spark Therapeutics (74/100), uniQure (81/100), REGENXBIO (74/100), Sarepta Therapeutics (83/100), Solid Biosciences (77/100), 4D Molecular Therapeutics (75/100), Voyager Therapeutics (74/100), Rocket Pharmaceuticals (78/100), Adverum Biotechnologies (82/100) |
Moz Domain Authority 40/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,411,402 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "MeiraGTx, a clinical-stage genetic medicine company with a global footprint, is focused on developing potentially curative treatments for patients living with serious diseases" (Meta description: 23 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is MeiraGTx?", Claude could identify the brand as of October 2026. MeiraGTx is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases, neurodegenerative disorders, and other conditions using adeno-associated virus (AAV) vector technology. It has a notable partnership with Johnson & Johnson (Janssen) Best known for Developing AAV-based gene therapies for inherited retinal diseases, including programs for achromatopsia and other eye conditions.
When asked "Best brands similar to MeiraGTx?", Claude would recommend MeiraGTx as of October 2026. It's a legitimate and recognized player in the gene therapy space, particularly for ocular and neurodegenerative diseases, so it would be relevant to mention alongside other gene therapy companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
MeiraGTx's main competitors in Healthcare: Spark Therapeutics (74/100), uniQure (81/100), REGENXBIO (74/100), Sarepta Therapeutics (83/100), Solid Biosciences (77/100).
Sources: Brand Analyzer scan
MeiraGTx has limited AI-search visibility, scoring 25/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 40, recommendation 50). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: MeiraGTx official site
MeiraGTx scores 50/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: MeiraGTx official site
MeiraGTx is a clinical-stage genetic medicine company with a global footprint. It focuses on developing potentially curative genetic therapies for patients living with serious rare and prevalent diseases, operating within the healthcare and biotechnology industry.
Sources: MeiraGTx official site
MeiraGTx can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: MeiraGTx official site
MeiraGTx develops genetic therapies intended to provide curative treatments for serious diseases. As a clinical-stage company, it works on researching, developing, and advancing gene therapy programs through clinical trials, targeting both rare and more prevalent conditions, and engages with healthcare providers, researchers, and biopharmaceutical partners in this process.
Sources: MeiraGTx official site
MeiraGTx's work is intended for patients suffering from serious rare and prevalent diseases. The company also engages with healthcare providers, researchers, and biopharmaceutical partners who are involved in the development, study, and potential delivery of its genetic therapies.
Sources: MeiraGTx official site
MeiraGTx is known for its focus on genetic medicine, specifically developing gene therapies aimed at curative treatment of serious diseases. It is recognized as a clinical-stage company with a global presence, positioning itself at the forefront of next-generation gene therapy innovation.
Sources: MeiraGTx official site
MeiraGTx scores 25/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
MeiraGTx has a weak AI-visibility profile at 25/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (50/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #1,411,402 (Tranco), a Moz Domain Authority of 40/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and thin schema.org structured data. In a live check, Claude could already identify MeiraGTx from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to MeiraGTx: Medtronic Diabetes (MiniMed) (79/100), MedPro Disposal (79/100), Mentor Arabia (79/100), Merck Animal Health (79/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.